Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/23/2019 10:29 PDT] SVRA SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/12/2019 10:30 PDT] Savara Inc. (NASDAQ:SVRA), Up By 100.00% ($8.41) From $8.410 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/09/2019 08:04 PDT] SVRA, Expected to Trade Lower After Bearish Insider Trading
• [04/03/2019 08:00 PDT] SVRA Expected to Trade Up After Bullish Patterns Develop
• [03/18/2019 08:00 PDT] SVRA Expected to Trade Down After Bearish Patterns Develop